| Document |
Document Title |
|
WO/2024/059559A1 |
The invention provides isothiazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or co...
|
|
WO/2024/059507A1 |
The disclosure provides a complex comprising (a) a first monomer comprising an Fc domain fused to two FGF21 domains comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which may be the same or different, and (b) a second ...
|
|
WO/2024/057195A1 |
The present invention relates to a pharmaceutical combination comprising 6α- ethyl -3α, 7 a- dihydroxy- 24 -nor- 5 β- cholan-23-ol or a pharmaceutically acceptable salt thereof and a statin and to a combination comprising 6α-ethyl-3Î...
|
|
WO/2024/058320A1 |
The present invention relates to a composition for preventing, alleviating, or treating an intestinal disease or malnutrition, and, according to the present invention, the composition can be used to alleviate a leaky gut phenomenon and i...
|
|
WO/2024/056678A1 |
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptak...
|
|
WO/2024/057352A1 |
Nausea and vomiting are unpleasant events induced by multiple triggers. Among them, drugs frequently prompt nnaauusseeaa and vomiting. Antitumor chemotherapeutics are among the most emetic drugs and often cause the so- called chemotherap...
|
|
WO/2024/056196A1 |
The present disclosure provides monoclonal antibodies, and method of use thereof, for diagnosing and/or treating P. gingivalis infection and/or chronic diseases resulted from or associated with such infection. Specific antigen¬ antibody...
|
|
WO/2024/059714A1 |
The present application generally relates to a method of treating advanced hepatic fibrosis with Formulation (I). Formulation (I) is a retinoid-conjugated lipid nanoparticle (LNP) containing HSP47 siRNA which prevents HSP47 protein trans...
|
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
|
WO/2024/055109A1 |
An oral hygiene chewing gum that is operable to provide a user detoxification and pH balancing of their mouth resulting in reduction of bacteria, control of halitosis and adsorption of harmful contaminants. The gum of the present inventi...
|
|
WO/2024/059718A1 |
Disclosed herein, are compositions comprising bacterial strains from Clostridia or Bacilli, and methods of treating obesity, metabolic syndrome, inflammatory bowel disease, as well as reducing weight gain, inhibiting lipid absorption in ...
|
|
WO/2024/056027A1 |
The present invention provides use of an ldh gene-containing lactobacillus plantarum in preparing a product for relieving enteritis. The lactobacillus plantarum or plasmid involved in the present invention is an ldh gene-containing lacto...
|
|
WO/2024/055983A1 |
A composition of a pumpkin seed protein or an isolated protein, protein hydrolysate or concentrated protein thereof, and the use thereof in the preparation of a drug, nutritional product, health-care product, food product, beverage and a...
|
|
WO/2024/055616A1 |
Provided is a Bacillus sp. strain X102, which was preserved in the Guangdong Microbial Culture Collection Center on June 9, 2022, with a preservation number of GDMCC No: 62531. The Bacillus sp. strain has bacteriostatic effects on gram-n...
|
|
WO/2024/059524A1 |
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/056825A1 |
Present application relates to a polypeptide comprising a sequence of an epitope from UreaseB, a polypeptide comprising a sequence of an epitope from UreaseB for use in preventing or treating a disease caused by Helicobacter pylori (H. p...
|
|
WO/2024/055976A1 |
A composition of a sunflower seed protein or an isolated protein, protein hydrolysate or concentrated protein thereof, and the use thereof in the preparation of a drug, nutritional product, health-care product, food product, beverage and...
|
|
WO/2024/057898A1 |
[Problem] To provide an antibacterial agent that is highly safe and inhibits, at a low concentration, the growth of oral bacteria such as Porphyromonas gingivalis causative of various diseases. [Solution] By using honeydew honey as an ac...
|
|
WO/2024/055810A1 |
Use of 6-phosphogluconic acid and a derivative thereof in preparing a medicament for preventing or treating glycometabolism disorder diseases. The 6-phosphogluconic acid and the derivative thereof are a type of cell glycometabolism regul...
|
|
WO/2024/051180A1 |
The present invention belongs to the technical field of microorganisms. Disclosed is use of phenyllactic acid in the preparation of a drug for inhibiting Helicobacter pylori infection. Phenyllactic acid inhibits antibiotic-resistant Heli...
|
|
WO/2024/054624A1 |
Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD). (Formula (I))
|
|
WO/2024/054155A1 |
The present invention relates to cell biology. In particular, the present invention teaches methods of contacting the cells with a LING complex inhibitor to inhibit durotaxis and, in consequence, reduce fibrosis and metastasis. Methods o...
|
|
WO/2024/055019A1 |
Provided are methods and systems for detection of oral bacteria.
|
|
WO/2024/054097A1 |
The present invention relates to a pharmaceutical composition comprising a metabolite of enavogliflozin, and a use thereof. An enavogliflozin M1 metabolite of chemical formula 1 is a SGLT1/SGLT2 dual inhibitor and exhibits a different ph...
|
|
WO/2024/052445A1 |
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is the CXCR3 antagonist 1-{(R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4- (2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazi...
|
|
WO/2024/047078A1 |
The present invention relates to (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5- yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol for use in the treatment of diabetic retinopathy, and its methods of treatment thereof.
|
|
WO/2024/047009A1 |
The present application concerns methods and uses for improving the balance of beneficial and deleterious bacteria in the gastrointestinal tract of aquatic species. It also concerns a method of culturing an aquaculture of an aquatic spec...
|
|
WO/2024/049994A1 |
Disclosed herein is a method of treating FAP to a patient in need of such treatment, comprising administering to the patient a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R9a is selected from the group c...
|
|
WO/2024/047130A1 |
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...
|
|
WO/2024/046208A1 |
Disclosed herein are a dihydroberberine composition and use thereof in the preparation of medicaments, nutritional products, health-care products, foods and beverages for regulating the intestinal flora. The dihydroberberine composition ...
|
|
WO/2024/048519A1 |
Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...
|
|
WO/2024/048683A1 |
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...
|
|
WO/2024/045255A1 |
Provided is a crystal form B of Tegoprazan. An X-ray powder diffraction pattern thereof has characteristic peaks at 2θ values of 9.5±0.2° and 14.1±0.2° and has one or more of the following characteristic peaks: 15.4±0.2°, 16.2±0....
|
|
WO/2024/046342A1 |
Disclosed are benzo bicyclic compounds and the use thereof in drugs. Specifically, the present invention relates to novel benzo bicyclic compounds and pharmaceutical compositions comprising said compounds. The present invention further r...
|
|
WO/2024/049207A1 |
The present invention relates to a novel microorganism, a lysate thereof, a culture broth thereof, an extract of the culture broth, vesicles therefrom, and anti-inflammatory and/or antibacterial uses thereof. A novel strain and vesicles ...
|
|
WO/2024/048593A1 |
A composition for improving nicotinamide mononucleotide (NMN) production, characterized by containing at least one carbohydrate selected from the group consisting of a monosaccharide (except glucose and xylose), a disaccharide, a trisacc...
|
|
WO/2024/046361A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or conditions related to the activity of RIPK1 kinase.
|
|
WO/2024/041460A1 |
The present invention provides compounds of Formula (I) : wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for the...
|
|
WO/2024/043298A1 |
The present invention addresses the problem of increasing the abundances of bacteria belonging to the genera Parabacteroides and Bifidobacterium in intestinal bacterial flora. Provided is a composition for improving intestinal bacterial ...
|
|
WO/2024/041609A1 |
The present invention relates to a benzo bicyclic compound and use thereof in a medicament, and specifically relates to a novel benzo bicyclic compound and a pharmaceutical composition comprising the compound. The present invention also ...
|
|
WO/2024/041633A1 |
Disclosed is use of a fused ring pyrimidine compound or a pharmaceutically acceptable salt thereof. The structure of the fused ring pyrimidine compound is represented by formula I. The fused ring pyrimidine compound can be used for prepa...
|
|
WO/2024/043728A1 |
The present invention relates to a pharmaceutical composition containing a Cnidium monnieri extract for the prevention or treatment of gastritis and gastric ulcer, and a food composition for the prevention or alleviation of gastritis and...
|
|
WO/2023/018803A9 |
Provided herein are antibody agents that bind specifically to GDF15, as well as compositions comprising GDF15 antibody agents, and methods of making and using the same.
|
|
WO/2024/041372A1 |
Provided are a branched polypeptide vector and a variant thereof. The branched polypeptide has a sequence set forth in the following: Xaa1(P2)-Xaa1-Xaa1(P1)-Xaa1-Xaa1(P2), or Xaa1(P1)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P1), or Xaa1(P2...
|
|
WO/2024/037841A1 |
The invention relates to a composition comprising rhubarb (Rheum palmatum) root extract and one or more additives selected from the group consisting of Acemannan and/or Glucomannan, or plant extracts containing said compounds for use in ...
|
|
WO/2024/039268A1 |
The present invention relates to the field of medicine, and more particularly to a method for treating a disease or disorder mediated by T-lymphocytes bearing a TRBV9 segment within the T-cell receptor, which includes administering an an...
|
|
WO/2024/037011A1 |
Provided are a culture medium and a method for inducing iPSC differentiation to obtain macrophages and use thereof, which relate to the technical field of biopharmaceutics. The culture medium comprises from a first-stage culture medium t...
|
|
WO/2024/036399A1 |
The present application includes a composition comprising manno- oligosaccharide (MOS) carbohydrates for use in inhibiting growth of pathogenic bacteria and/or promoting growth of beneficial bacteria in a subject, wherein at least 70% wt...
|
|
WO/2024/039250A1 |
The present invention relates to a new class of methanogen inhibitors for ruminants. The invention also extends to the use of such compounds in ruminants to reduce methane production in the rumen and/or to enhance productivity in the rum...
|
|
WO/2024/039593A1 |
This invention relates to a ready to use, orally administered formulation containing a therapeutically effective amount of calcium as calcium succinate monohydrate with unexpected palatability, chemical and physical stability, and availa...
|
